home *** CD-ROM | disk | FTP | other *** search
/ Cancer - Principles & Practice of Oncology / Oncology.iso / PPO / CHAP35 / T4_2.GIF < prev    next >
Graphics Interchange Format  |  1999-06-07  |  81KB  |  405x400  |  8-bit (240 colors)
Labels: bulletin board | earth | poster | reckoner | sky | web site
OCR: LOW- -RISK (SINGLE AGENTS Methotrexate*: -30 -50 mg/m IM weekly; 0.4 mg/kg IM IV daily X 5 days (repeat in wk); or mg/kg IM or IV on days 5. and (repeat in 9 wk) plus folinic acid (leucovorin), 0.1 mg/kg or IV days and Dactinomycin .25 mg/m2 IV (repeat in 9 wk), or 10 ug/kg (up to 0.5 mg) IV daily d (repeat wk INTERMEDIATE OR HIGH-RISK (DRUG COMBINATIONS EMA-CO consists of alternating cyeles of EMA (days 1 and 2 and CO (day Day EMA: etoposide, 100 mg/m2 IV and dactinomycin, 0.5 mg IV: and methotrexate, 100 mg push followed by 200 mg/m2 12-h TV Day EMA: etoposide 100 mg/m IV dactinomycin, 0.5 mg IV and folinic acid, 15 mg IV or PO every 2 after start of methotrexate Day CO vencristine mg/ /m IV and cyclophosphamide 600 mg/m TV SALVAGE REGIMENS INVESTIGATIONAL DRUGS AND COMBINATIONS) PEBA: c ...